Advancements in Biochemical Markers and Clinical Evaluation Techniques for Accurate Diagnosis of Coronary Artery Disease

Coronary Artery Disease (CAD) is one of the leading causes of morbidity and mortality worldwide, characterized by the narrowing or blockage of coronary arteries due to atherosclerosis. Early and accurate diagnosis of CAD is critical for effective management and prevention of adverse cardiac events. Traditionally, clinical evaluation techniques such as patient history, physical examination, electrocardiography (ECG), and imaging modalities have been used for diagnosis. However, these approaches often lack sensitivity and specificity in detecting early or asymptomatic stages of the disease. Recent advancements in biochemical markers have significantly improved the diagnostic landscape of CAD. Biomarkers such as high-sensitivity cardiac troponins (hs-cTn), C-reactive protein (CRP), B-type natriuretic peptide (BNP), myoglobin, and lipoprotein-associated phospholipase A2 (Lp-PLA2) provide valuable insights into myocardial injury, inflammation, and plaque instability. These markers enable early detection and risk stratification, thereby enhancing clinical decision-making. This research paper examines the integration of advanced biochemical markers with modern clinical evaluation techniques for accurate diagnosis of CAD. The study adopts a qualitative and analytical approach using secondary data from peer-reviewed journals and clinical studies. It highlights the role of emerging diagnostic technologies, including high-resolution imaging, artificial intelligence, and point-of-care testing, in improving diagnostic accuracy. The findings suggest that integrated diagnostic approaches combining clinical assessment with biochemical analysis offer superior sensitivity and specificity compared to traditional methods. However, challenges such as cost, accessibility, and lack of standardization remain significant barriers. The paper concludes that advancements in biomarkers and clinical techniques have revolutionized CAD diagnosis, enabling earlier detection and personalized treatment strategies. Future research should focus on developing cost-effective, accessible, and standardized diagnostic tools to ensure widespread implementation, particularly in resource-limited settings.